Domain Associates
Venture capitalPrinceton · Seed–Growth · 11 people tracked
Also known as DOMAIN ASSOCIATES, LLC
Find your way into Domain Associates
663 people in our graph share verified history with the Domain Associates team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Domain Associates focuses on the biotech sector, having pioneered the first venture capital fund dedicated to biotech and managing multiple subsequent biotech-focused venture funds.
Source: firm website, verified Sep 15, 2026.
Team · 11 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Domain Associates went on to found or lead other companies.
What they invest in
from 33 of 43 portfolio companiesBiotech ×28Healthtech ×19Medical Devices ×9Deep Tech ×3Digital Health ×3AI & Machine Learning ×2Consumer ×1Direct to Consumer ×1
HQs:United States×33
Investments · showing 32 of 43
founders shown can be your intro pathBy year:2026 · 12024 · 12021 · 12020 · 12016 · 12015 · 72014 · 22012 · 115 dated
Aldeyra Therapeutics is a biopharmaceutical company developing therapies for eye diseases and other conditions.
BiotechHealthtechMedical DevicesLexington, US
Todd C. Brady(Executive Officer, Director)inStephen Tulipano(Executive Officer)inScott L. Young(Executive Officer)inDr. Brady(President and Chief Executive Officer)
BoardJesse I. Treu(Director)inBen Bronstein(Director)
Board seatJesse Treu· per SEC Form D
Bionano develops optical genome mapping (OGM) systems and analysis software that detect structural variants and chromosomal aberrations across the genome.
BiotechHealthtechMedical DevicesSan Diego, US
Han Cao(Executive Officer)Gulsen Kama(Executive Officer)Mark Oldakowski(Executive Officer)inJonathan Dixon(Executive Officer)inR. Erik Holmlin(Executive Officer, Director)Alka Chaubey(Executive Officer)in
Board seatBrian Halak· per SEC Form D · $68.4M raise · filed Jan 2015
Co-investorsHudson Bay
Evofem Biosciences is a biopharmaceutical company that commercializes products for women's sexual and reproductive health, including PHEXX, a non-hormonal prescription vaginal contraceptive gel applied before intercourse, and SOLOSEC, an oral antimicrobial agent for treating bacterial vaginosis and trichomoniasis.
BiotechSan Diego, US
Ivy Zhang(Executive Officer)inSaundra Pelletier(Executive Officer, Director)inKelly Culwell(Executive Officer)inJustin J. File(Executive Officer)inAlexander A. Fitzpatrick(Executive Officer)Russell Barrans(Executive Officer)
Board seatKim Kamdar· per SEC Form D · $25M raise · filed May 2020
Co-investorsInvescoWoodford Investment Management
Atara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease.
BiotechHealthtechMedical DevicesThousand Oaks, US
AnhCo Nguyen(President and Chief Executive Officer)
Co-investorsDag VenturesEcoR1 CapitalHEALTHCARE ROYALTY PARTNERSKleiner PerkinsFidelity Investments
Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms.
BiotechHealthtechMedical DevicesLexington, US
HARITH RAJAGOPALAN(Executive Officer, Director)inJAY CAPLAN(Executive Officer, Director)inJay Caplan(Executive Officer, Director)inHarith Rajagopalan(Executive Officer, Director)inLISA DAVIDSON(Executive Officer)inDiane Marcou(Executive Officer)in
Co-investorsBessemer Venture PartnersCatalio Capital Management, LPEmergent Medical Partners, LLPGeneral CatalystMITHRILMithril Capital Management+2 more
.png)
Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.
BiotechDigital HealthFemTechHealthtechSalt Lake City, US
Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in
BoardMansoor Mirza(Director)
Co-investorsaMoonExcelestar VenturesOUP (Osage University Partners)UpStart VenturesVivo CapitalCatalyst Health Ventures
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsForesite CapitalPappas CapitalSofinnova VenturesvenBio PartnersBlackRockMPM BioImpact
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDamien McDevitt(President and Chief Executive Officer)in
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedEDB InvestmentsSection 32Frazier Life Sciences+3 more
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesMedical Excellence CapitalOS Fund
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsPappas CapitalFidelity InvestmentsJennison AssociatesThird Rock Ventures
Currax Pharmaceuticals develops and markets a portfolio of therapies for chronic progressive diseases.
BiotechHealthtechLa Jolla, US
Preston Klassen(Executive Officer)inJoseph Hagan(Executive Officer)Michael Narachi(Executive Officer, Director)Thomas Cannell(Executive Officer)
BoardBrian H. Dovey(Director)in
Board seatBrian DoveyEckard Weber· per SEC Form D · $90M raise · filed Sep 2015
Co-investorsCross Creek AdvisorsNew Enterprise Associates (NEA)Sofinnova VenturesDomain Partners
HealthtechDuluth, US
Anthony V. Lando(Executive Officer, Director)inTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in
BoardRebecca B. Robertson(Director)
Board seatJesse Treu· per SEC Form D
Co-investorsAccuitive Medical VenturesVersant Ventures
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Board seatBrian Halak· per SEC Form D · $125.5M raise · filed Jun 2026
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesMedical Excellence CapitalVivo Capital+1 more
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Biopharmaceutical developer of tumor-selective PARP inhibitor cancer therapies, acquired by Sanofi-aventis in 2009.
Co-investorsAisling CapitalAsset Management CompanyCanaan PartnersKleiner PerkinsSPRINGROCK VENTURESVantagePoint Capital Partners
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechHealthtechMedical DevicesCarlsbad, US
Paul Flook(Executive Officer, Director)inGregory J. Gosch(Executive Officer, Director)Lynne Rollins(Executive Officer)Aditya Rajagopal(Director)inAxel Scherer(Director)
BoardJustin Klein(Director)in
Co-investorsAdjuvant CapitalGlobal BrainMoore Venture PartnersNew Enterprise Associates (NEA)Windham Capital PartnersDomain Partners+2 more
Colorescience is a professional skincare brand that develops mineral-based sun protection (SPF), skincare, and color correction products, originally created for post-procedure skin and marketed for all ages and skin types.
ConsumerDirect to ConsumerHealthtechWellness & FitnessCarlsbad, US
Stephen Loomis(Executive Officer)Mary Fisher(Executive Officer, Director)inTheodore Ebel(Executive Officer)Josie Juncal-Schwarz(Executive Officer)
BoardM Bolyard(Director)Brian Dovey(Director)in
Co-investors1315 CapitalAisling CapitalHealthCare Ventures, LLCLongwood FundRoundTable Healthcare PartnersSplit Rock Partners
GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials.
BiotechHealthtechLogistics & Supply Chain
Co-investorsCross Creek Advisors
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.
AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US
Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)inNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in
BoardGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BARY BAILEY(Director)
Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCLongitude CapitalStarlight Ventures
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesCanaan PartnersConnecticut InnovationsSofinnova VenturesFlare Capital Partners+1 more
San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.
Co-investorsARCH Venture PartnersDecheng CapitalALTITUDE LIFE SCIENCE VENTURESHillhouse CapitalNan Fung Life Sciences
Thermo Fisher provides life science products and laboratory equipment, including antibodies, consumables, biobanking resources, and Cryo-EM imaging systems for research labs and scientists.
BiotechEnterprise SoftwareHardwareHealthtechWaltham, US
Anthony Uzzo(Executive Officer, Director)inJoshua Geballe(Executive Officer, Director)James Gregory(Executive Officer, Director)Marc N. Casper(Executive Officer, Director)inAndrew J. Thomson(Executive Officer)Peter M. Wilver(Executive Officer)
Co-investorsARCH Venture PartnersBayMed Venture PartnersCross Creek AdvisorsExcel Venture ManagementHeran PartnersOak HC/FT+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CoLucid PharmaceuticalsKona MedicalTragara PharmaceuticalsAdynxxAxial BiotherapeuticsCoDa TherapeuticsExalys TherapeuticsMiramar LabsSequent MedicalZyga Technology
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 12
8 IPOs · 4 acquisitions · showing 8Aldeyra TherapeuticsNASDAQ: ALDXBionano GenomicsNASDAQ: BNGOEvofem BiosciencesOTC: EVFMAtara BiotherapeuticsNASDAQ: ATRAFractylNASDAQ: GUTSSera PrognosticsNASDAQ: SERASyndax PharmaceuticalsNASDAQ: SNDXGenVaultacq. by Thermo Fisher Scientific
Portfolio news
latest coverage across their companiesThermo Fisher Scientific · investing.com · Sep 16, 2026
Sera Prognostics · news.alphastreet.com · Aug 20, 2026
Bionano Genomics · stocktitan.net · Aug 14, 2026
Syndax Pharmaceuticals · aol.com · Aug 12, 2026
Adynxx · morningstar.com · Aug 11, 2026
Aldeyra Therapeutics · stocktitan.net · Aug 6, 2026
SonoThera · statnews.com · Jul 17, 2026
Fund performance · per public LP disclosures
as of Mar 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Domain Excelsior Fund, LPLPs: Empire State Development – New York Ventures | 2022 | — | — | 12.49x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 5
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Atara Biotherapeutics | 7.0% | $52.00 | Jul 2015 | $101.8M |
| Fractyl | 8.4% | $15.00 | Feb 2024 | $60M |
| Sera Prognostics | 8.4% | $16.00 | Jul 2021 | $41.2M |
| Syndax Pharmaceuticals | 14.6% | $12.00 | Mar 2016 | $30.5M |
| Aldeyra Therapeutics | 20.8% | $7.50 | May 2015 | $14.9M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Domain Associates made?
- Domain Associates has 43 tracked investments, 12 of which have exited, including 1 dated in the last 24 months.
- What stage does Domain Associates invest at?
- Domain Associates invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Domain Associates's typical check size?
- Domain Associates typically writes checks of $200K – $15M.
- What sectors does Domain Associates focus on?
- Domain Associates focuses on Biotech.
- Where is Domain Associates located?
- Domain Associates is headquartered in Princeton, US.
Co-investors · 35
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'
Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Seventure Partners is a European venture capital firm, founded in 1997 and a subsidiary of Natixis Investment Managers, investing in digital technologies and life sciences companies with strong growth potential.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
▶23 more co-investors
Pontifax Venture CapitalUnknown VenturesMeritech Capital PartnersVenrockWildcat Venture PartnersForbionJohnson & Johnson Innovation – JJDCDeerfield Management CompanyAbingworthStanford UniversityPivotal Life SciencesFrazier Healthcare PartnersRiverVest Venture PartnersNew Leaf Venture PartnersAlta PartnersAmplitude Venture CapitalOkapi Venture CapitalJDRF T1D FundSante VenturesCincyTechRTW Investments L.P.Avedro, Inc.BioInnovation Capital
Firms observed investing alongside Domain Associates, from public investor directories. Shared companies are the overlap with Domain Associates's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Kinnevik is a leading growth investor, active owner, and operational partner providing patient capital to technology-enabled challenger businesses in Europe and the US.